Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885

Alex Y. Chang; Z. Nora Tu; George T. Bryan; John M. Kirkwood; Martin M. Oken; Donald L. Trump

doi:10.1007/BF00874447

Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885

Alex Y. Chang, Z. Nora Tu, George T. Bryan, John M. Kirkwood, Martin M. Oken, Donald L. Trump

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Seventeen patients were treated with echinomycin for metastatic renal cell carcinoma. Echinomycin is a bifunctional DNA intercalating agent with broad preclinical antitumor activity. It was given at 1200 mg/m² by intravenous infusion over 30-60 min weekly for 4 weeks. The treatment was repeated every 6 weeks. There were no responses observed in the study. No life threatening or lethal toxicity was documented in 13 eligible patients. The median survival of these patients was 13.7 months. We conclude that echinomycin is not active against metastatic renal cell carcinoma at the dose and schedule tested.

Original language	English (US)
Pages (from-to)	151-153
Number of pages	3
Journal	Investigational New Drugs
Volume	12
Issue number	2
DOIs	https://doi.org/10.1007/BF00874447
State	Published - Jun 1994
Externally published	Yes

Keywords

echinomycin
metastatic renal cell carcinoma

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00874447

Cite this

@article{013d85e284174090a873799cd2d3c178,

title = "Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885",

abstract = "Seventeen patients were treated with echinomycin for metastatic renal cell carcinoma. Echinomycin is a bifunctional DNA intercalating agent with broad preclinical antitumor activity. It was given at 1200 mg/m2 by intravenous infusion over 30-60 min weekly for 4 weeks. The treatment was repeated every 6 weeks. There were no responses observed in the study. No life threatening or lethal toxicity was documented in 13 eligible patients. The median survival of these patients was 13.7 months. We conclude that echinomycin is not active against metastatic renal cell carcinoma at the dose and schedule tested.",

keywords = "echinomycin, metastatic renal cell carcinoma",

author = "Chang, {Alex Y.} and Tu, {Z. Nora} and Bryan, {George T.} and Kirkwood, {John M.} and Oken, {Martin M.} and Trump, {Donald L.}",

year = "1994",

month = jun,

doi = "10.1007/BF00874447",

language = "English (US)",

volume = "12",

pages = "151--153",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885

AU - Chang, Alex Y.

AU - Tu, Z. Nora

AU - Bryan, George T.

AU - Kirkwood, John M.

AU - Oken, Martin M.

AU - Trump, Donald L.

PY - 1994/6

Y1 - 1994/6

N2 - Seventeen patients were treated with echinomycin for metastatic renal cell carcinoma. Echinomycin is a bifunctional DNA intercalating agent with broad preclinical antitumor activity. It was given at 1200 mg/m2 by intravenous infusion over 30-60 min weekly for 4 weeks. The treatment was repeated every 6 weeks. There were no responses observed in the study. No life threatening or lethal toxicity was documented in 13 eligible patients. The median survival of these patients was 13.7 months. We conclude that echinomycin is not active against metastatic renal cell carcinoma at the dose and schedule tested.

AB - Seventeen patients were treated with echinomycin for metastatic renal cell carcinoma. Echinomycin is a bifunctional DNA intercalating agent with broad preclinical antitumor activity. It was given at 1200 mg/m2 by intravenous infusion over 30-60 min weekly for 4 weeks. The treatment was repeated every 6 weeks. There were no responses observed in the study. No life threatening or lethal toxicity was documented in 13 eligible patients. The median survival of these patients was 13.7 months. We conclude that echinomycin is not active against metastatic renal cell carcinoma at the dose and schedule tested.

KW - echinomycin

KW - metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027949392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027949392&partnerID=8YFLogxK

U2 - 10.1007/BF00874447

DO - 10.1007/BF00874447

M3 - Article

C2 - 7860234

AN - SCOPUS:0027949392

SN - 0167-6997

VL - 12

SP - 151

EP - 153

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this